Table 1 Main characteristics of the discovery sample
From: DNA methylation and stroke prognosis: an epigenome-wide association study
Whole sample (N = 316) | Good outcome (N = 150) | Poor outcome (N = 166) | p-value | |
|---|---|---|---|---|
Age, years | 77.5 (69.0;83.0) | 76.0 (65.0;81.0) | 79.0 (71.2;84.0) | 0.001 |
Sex, female | 152 (48.1%) | 62 (41.3%) | 90 (54.2%) | 0.030 |
Hypertension | 236 (74.7%) | 109 (72.7%) | 127 (76.5%) | 0.513 |
Dyslipidemia | 138 (43.8%) | 71 (47.7%) | 67 (40.4%) | 0.235 |
Diabetes | 129 (40.8%) | 64 (42.7%) | 65 (39.2%) | 0.604 |
Atrial fibrillation | 176 (55.7%) | 73 (48.7%) | 103 (62.0%) | 0.023 |
Smoking | 85 (26.9%) | 48 (32.0%) | 37 (22.3%) | 0.069 |
Toast | 0.016 | |||
Atherothrombotic | 108 (34.2%) | 56 (37.3%) | 52 (31.3%) | |
Cardioembolic | 184 (58.2%) | 77 (51.3%) | 107 (64.5%) | |
Undetermined | 24 (7.60%) | 17 (11.33%) | 7 (4.22%) | |
Baseline NIHSS | 8.0 (5.0;17.0) | 5.0 (4.0;8.0) | 15.0 (7.0;19.0) | < 0.001 |
NIHSS 24 h | 7.0 (4.0;14.0) | 4.0 (2.0;6.0) | 13.0 (7.0;19.0) | < 0.001 |
rTPA treatment | 77 (24.5%) | 36 (24.2%) | 41 (24.8%) | 0.992 |
Previous mRS | < 0.001 | |||
0 | 224 (70.9%) | 127 (84.7%) | 97 (58.4%) | |
1 | 45 (14.2%) | 14 (9.33%) | 31 (18.7%) | |
2 | 47 (14.9%) | 9 (6.00%) | 38 (22.9%) | |
3-month mRS | – | |||
0 | 46 (14.6%) | – | – | |
1 | 46 (14.6%) | – | – | |
2 | 58 (18.4%) | – | – | |
3 | 47 (14.9%) | – | – | |
4 | 47 (14.9%) | – | – | |
5 | 6 (1.90%) | – | – | |
6 | 66 (20.9%) | – | – |